Welcome to our dedicated page for ELOXD SEC filings (Ticker: ELOXD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELOXD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELOXD's regulatory disclosures and financial reporting.
Eloxx Pharmaceuticals disclosed that Coastlands-related reporting persons collectively beneficially own 410,530 shares of Common Stock, representing 9.99% of the class. The filing states the calculation uses 4,036,314 shares outstanding as of June 10, 2026 from the issuer's final prospectus.
The reported position comprises 337,431 shares owned and 73,099 shares issuable upon exercise of pre-funded warrants, with the 9.99% beneficial ownership limitation applied and excess pre-funded warrants excluded.
Eloxx Pharmaceuticals disclosed that Coastlands-related reporting persons collectively beneficially own 410,530 shares of Common Stock, representing 9.99% of the class. The filing states the calculation uses 4,036,314 shares outstanding as of June 10, 2026 from the issuer's final prospectus.
The reported position comprises 337,431 shares owned and 73,099 shares issuable upon exercise of pre-funded warrants, with the 9.99% beneficial ownership limitation applied and excess pre-funded warrants excluded.
Eloxx Pharmaceuticals ownership disclosure: A group of related investment entities and Daniel Simon report shared beneficial ownership of common stock totaling individual stakes up to 854,973 shares (19.99%) as of filings signed 06/17/2026. The filing states these securities are directly owned by advisory clients of Domicilium Capital Partners LLC.
The schedule lists multiple related holders with reported holdings: BKJLAGG, LLC 602,266 shares (14.1%), and several entities holding between 238,422 and 240,688 shares. The filing notes a 19.99% beneficial ownership limitation and excludes pre-funded warrants in excess of that limit.
Eloxx Pharmaceuticals ownership disclosure: A group of related investment entities and Daniel Simon report shared beneficial ownership of common stock totaling individual stakes up to 854,973 shares (19.99%) as of filings signed 06/17/2026. The filing states these securities are directly owned by advisory clients of Domicilium Capital Partners LLC.
The schedule lists multiple related holders with reported holdings: BKJLAGG, LLC 602,266 shares (14.1%), and several entities holding between 238,422 and 240,688 shares. The filing notes a 19.99% beneficial ownership limitation and excludes pre-funded warrants in excess of that limit.
Eloxx Pharmaceuticals, Inc. reported that 10% owner Domicilium Real Estate Fund III LP, through affiliated investment entities, restructured its position in pre-funded warrants and common stock. Several transactions coded "J" as "other acquisition or disposition" reflect exchanges of Pre-Funded Warrants into common shares pursuant to their terms.
Footnotes state that each Pre-Funded Warrant was exchanged for one share of Eloxx common stock and that the warrants have no expiration date and are exercisable at any time, subject to a 19.99% beneficial ownership cap. All holdings are reported as indirect, through funds and LLCs advised by Domicilium and managed by Daniel Simon. No open-market purchases or sales are reported in this filing.
Eloxx Pharmaceuticals, Inc. reported that 10% owner Domicilium Real Estate Fund III LP, through affiliated investment entities, restructured its position in pre-funded warrants and common stock. Several transactions coded "J" as "other acquisition or disposition" reflect exchanges of Pre-Funded Warrants into common shares pursuant to their terms.
Footnotes state that each Pre-Funded Warrant was exchanged for one share of Eloxx common stock and that the warrants have no expiration date and are exercisable at any time, subject to a 19.99% beneficial ownership cap. All holdings are reported as indirect, through funds and LLCs advised by Domicilium and managed by Daniel Simon. No open-market purchases or sales are reported in this filing.
Domicilium Real Estate Fund III LP filed an initial ownership report for Eloxx Pharmaceuticals, Inc. as a greater-than-10% holder. The filing shows indirect ownership of 14,285 shares of Eloxx common stock.
The fund also indirectly holds several Pre-Funded Warrants to purchase Eloxx common stock, with underlying share amounts of 611,317, 361,578, 1,196,067 and 238,422 shares. These warrants are exercisable at an exercise price of $0.1100 per share and have no expiration date. A footnote states that holders may not exercise Pre-Funded Warrants if, after exercise, they would beneficially own more than 19.99% of Eloxx’s outstanding common stock.
The securities are held through entities including Domicilium Real Estate Fund III LP, BKJLAGG, LLC, MSEK Charleston LLC and Bold Stroke Investments, LLC, and may be deemed indirectly beneficially owned by Domicilium Capital Partners LLC, its affiliates and Daniel Simon.
Domicilium Real Estate Fund III LP filed an initial ownership report for Eloxx Pharmaceuticals, Inc. as a greater-than-10% holder. The filing shows indirect ownership of 14,285 shares of Eloxx common stock.
The fund also indirectly holds several Pre-Funded Warrants to purchase Eloxx common stock, with underlying share amounts of 611,317, 361,578, 1,196,067 and 238,422 shares. These warrants are exercisable at an exercise price of $0.1100 per share and have no expiration date. A footnote states that holders may not exercise Pre-Funded Warrants if, after exercise, they would beneficially own more than 19.99% of Eloxx’s outstanding common stock.
The securities are held through entities including Domicilium Real Estate Fund III LP, BKJLAGG, LLC, MSEK Charleston LLC and Bold Stroke Investments, LLC, and may be deemed indirectly beneficially owned by Domicilium Capital Partners LLC, its affiliates and Daniel Simon.
Eloxx Pharmaceuticals, Inc. Schedule 13G filing shows EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman reporting shared beneficial ownership of common stock. The filing lists 403,586 shares (EcoR1 and Mr. Nodelman) and 377,635 shares (Qualified Fund), representing 9.9% and 9.3% of the class respectively. The percentages are calculated using 4,036,314 shares outstanding following an offering disclosed in a prospectus filed 06/09/2026. The reporting persons state the holdings were not acquired to change control and disclaim group membership beyond the joint filing.
Eloxx Pharmaceuticals, Inc. Schedule 13G filing shows EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman reporting shared beneficial ownership of common stock. The filing lists 403,586 shares (EcoR1 and Mr. Nodelman) and 377,635 shares (Qualified Fund), representing 9.9% and 9.3% of the class respectively. The percentages are calculated using 4,036,314 shares outstanding following an offering disclosed in a prospectus filed 06/09/2026. The reporting persons state the holdings were not acquired to change control and disclaim group membership beyond the joint filing.
Eloxx Pharmaceuticals reports a Schedule 13G filing showing Stonepine-affiliated filers beneficially own 403,228 shares of Common Stock, equal to 9.9% of the class. The filing states the position comprises 400,000 shares and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as reported in the issuer's June 9, 2026 prospectus. The reporting persons disclaim group membership and disavow beneficial ownership beyond their pecuniary interest; shared voting and dispositive power are reported for 403,228 shares.
Eloxx Pharmaceuticals reports a Schedule 13G filing showing Stonepine-affiliated filers beneficially own 403,228 shares of Common Stock, equal to 9.9% of the class. The filing states the position comprises 400,000 shares and pre-funded warrants to acquire 50,000 shares, subject to a 9.99% beneficial ownership limitation. The percentage is calculated using 4,036,314 shares outstanding immediately after the offering, as reported in the issuer's June 9, 2026 prospectus. The reporting persons disclaim group membership and disavow beneficial ownership beyond their pecuniary interest; shared voting and dispositive power are reported for 403,228 shares.
Eloxx Pharmaceuticals reported that certain affiliated investment entities led by Invus and Avicenna hold aggregate beneficial interests in its common stock. As of June 9, 2026, the Reporting Persons beneficially owned 403,586 shares (an aggregate of 400,000 shares and 3,586 warrants) representing 9.99% of issued and outstanding shares. The filing states Invus Public Equities directly held 350,525 shares and 43,816 pre-funded warrants, and Avicenna Fund directly held 49,475 shares and 6,184 pre-funded warrants. Shares outstanding used for the percentage calculation were 4,036,314 as of June 10, 2026. A Beneficial Ownership Limitation prevents exercises that would exceed 9.99%.
Eloxx Pharmaceuticals reported that certain affiliated investment entities led by Invus and Avicenna hold aggregate beneficial interests in its common stock. As of June 9, 2026, the Reporting Persons beneficially owned 403,586 shares (an aggregate of 400,000 shares and 3,586 warrants) representing 9.99% of issued and outstanding shares. The filing states Invus Public Equities directly held 350,525 shares and 43,816 pre-funded warrants, and Avicenna Fund directly held 49,475 shares and 6,184 pre-funded warrants. Shares outstanding used for the percentage calculation were 4,036,314 as of June 10, 2026. A Beneficial Ownership Limitation prevents exercises that would exceed 9.99%.